Story
Biogen Stock Climbs on Analyst Upgrades Ahead of Key Alzheimer's Drug Catalysts
Biogen (BIIB) shares rose 1.6% in pre-open trading as a flurry of Wall Street analyst upgrades bolstered investor confidence ahead of two significant pipeline catalysts for the company's Alzheimer's franchise. The stock traded at $202.17, up from its previous close of $198.91, amid a broadly positive market session.
Analyst Optimism Drives Gains
The rally was underpinned by several analyst price target increases, signaling renewed enthusiasm for the stock. The positive revisions included:
- Jefferies: Target raised to $255 from $210
- RBC Capital: Target raised to $242 from $227
- BofA Securities: Target raised to $217 from $203
These firms largely maintained their buy-equivalent ratings, pointing to two key upcoming events that could significantly impact Biogen's long-term outlook. The first is the presentation of detailed Phase 2 data for its Alzheimer's candidate diranersen at the AAIC conference in mid-July. The second is an anticipated FDA decision by August on a once-weekly subcutaneous starting dose for Leqembi, its partnered Alzheimer's treatment.
AdPipeline Catalysts and Market Impact
An approval for the subcutaneous Leqembi formulation would represent a meaningful commercial expansion, according to market observers. It would allow patients to begin treatment at home, a significant convenience factor beyond the currently approved weekly at-home maintenance dosing. This development could help accelerate the drug's uptake and revenue potential.
Broader market sentiment also provided a supportive backdrop. HSBC analysts noted in a report that biopharma M&A is trending toward a record year, citing Biogen's purchase of Apellis as a notable transaction. While Biogen faces near-term earnings pressure from elevated R&D and milestone charges—projected to cause a roughly 40% year-over-year EPS decline in the second quarter—investors appeared to focus on the longer-term growth drivers.